Can Chen1#, Ranyi Li1#,
Shuliang Xing2, Lei Cao3, Yue
Qu4, Qianzhou Lv1 , Xiaoyu
Li1*, Zhangzhang Chen1*
1Department of Pharmacy, Zhongshan Hospital, Fudan
University, Shanghai, China
2Science and Education office, Shanghai Geriatric
Medical Center, Shanghai, China
3Medical Administration Office, Zhongshan Hospital,
Fudan University, Shanghai, China
4Department of Infectious Diseases, The Alfred
Hospital and Monash University, Clayton, VIC 3000, Australia
# Can Chen and Ranyi Li contributed equally to this
work and have shared first authorship.
*Corresponding authors:
Zhangzhang Chen, Department of Pharmacy, Zhongshan Hospital, Fudan
University, 180# Fengling Road, 200032, Shanghai, China, Tel:
+86-21-64041990-5062. Email: chen.zhangzhang@zs-hospital.sh.cn,
Xiaoyu Li, Department of Pharmacy, Zhongshan Hospital Fudan University,
180# Fengling Road, 200032, Shanghai, China, Tel: +86-21-64041990-5063.
Email: Li.xiaoyu@zs-hospital.sh.cn
Key words: Nirmatrelvir-ritonavir, COVID-19, observational
study